title: Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer.
abstract: Trastuzumab has been the standard treatment in first-line treatment of HER-2-positive advanced breast cancer (H2ABC). This study explored whether the delayed and repeated use of trastuzumab could influence overall survival (OS). A total of 128 patients with H2ABC who had received at least one line of trastuzumab-based regimens were included. The primary endpoint was OS defined as from the date of first diagnosis of H2ABC to death. The median OS of initiating trastuzumab in first-line group (n = 56), in the second-line group (n = 32), and the third- or more-line group (n = 40) was 40.6 m, 39.5 m, and 38 m, respectively (P = 0.867). For patients who had received over one line of trastuzumab (n = 46), the median OS was 44 m, and for those receiving only one line (n = 67), it was 27.6 m (P = 0.059). The delayed use of trastuzumab has no negative effect on the OS of patients with H2ABC. There is a trend of improved OS over the repeated use of trastuzumab.
authors.affiliation: State Key Laboratory of Oncology in Southern China & Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, Guangdong, People's Republic of China.
authors.forename: Yan-Xia
authors.initials: YX
authors.lastname: Shi
authors.forename: Yu-Ting
authors.initials: YT
authors.lastname: Tan
authors.forename: Zhong-Yu
authors.initials: ZY
authors.lastname: Yuan
authors.forename: Shu-Sen
authors.initials: SS
authors.lastname: Wang
authors.forename: Rou-Jun
authors.initials: RJ
authors.lastname: Peng
authors.forename: Xin
authors.initials: X
authors.lastname: An
authors.forename: Ye
authors.initials: Y
authors.lastname: Cao
authors.forename: Ying
authors.initials: Y
authors.lastname: Jin
authors.forename: Xiu-Yu
authors.initials: XY
authors.lastname: Cai
authors.forename: Yue-Li
authors.initials: YL
authors.lastname: Sun
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Teng
authors.forename: Dong-Geng
authors.initials: DG
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D016017:Odds Ratio; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D012189:Retrospective Studies; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab